Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Ultrasound-Guided Diagnosis of Lung Cancer
share announcement

Ultrasound-Guided Diagnosis of Lung Cancer

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 2914

Special Issue Editor

Prof. Dr. Chao-Chi Ho

E-Mail
Guest Editor
Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan
Interests: EBUS TBB; EBUS TBNA; cancer biology and treatment of lung cancer

Special Issue Information

Dear Colleagues,

Lung cancer is the leading cause of cancer-related deaths worldwide. The cytopathological diagnosis of lung cancer is imperative since the distinction between malignant and benign lesions is essential. Furthermore, the increased use of markers and genotyping warrants a better quality and larger tissue when performing invasive procedures. However, liquid biopsy can detect genetic alternations of lung cancer. Not all patients had detectable circulating tumor DNA (ctDNA) in the blood. Ultrasound-guided diagnosis, including ultrasound-guided transthoracic needle biopsy (US-TTNB), endobronchial ultrasound transbronchial biopsy (EBUS TBB) or endobronchial ultrasound transbronchial needle aspiration/biopsy (EBUS TBNA) have been used for pathologic diagnosis or/and staging. US-TTNB is a safe procedure with a very low risk of complications. Centrally located lung lesions and mediastinal lymph nodes can be biopsied using EBUS TBB or EBUS TBNA. Additionally, the use of EBUS TBB for peripheral lung tumors has gradually increased because computed tomography-guided biopsy has a high complication rate.

This Special Issue aims to provide the pulmonologist, chest surgeons and oncologists with updated evidence to support the use of ultrasound-guided biopsy for lung cancer diagnosis. Several techniques improve diagnostic accuracy: ultrasound elastography is used to predict the possibility of malignancy; fluoroscopy, virtual bronchoscopic navigation or cone-beam CT (CBCT), has been attempted to improve diagnostic accuracy. Rapid on site evaluation (ROSE) also improved diagnostic accuracy. We will be collecting reviews or original data on the potential application of ultrasound-guided diagnosis in order to improve diagnostic ability, accuracy and increase the amount of tissue.

Prof. Dr. Chao-Chi Ho
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Lung cancer
  • Ultrasound-guided biopsy
  • Ultrasound guided transthoracic needle biopsy (US-TTNB)
  • Endobronchial ultrasound transbronchial biopsy (EBUS TBB)
  • Endobronchial ultrasound transbronchial needle aspiration/biopsy (EBUS TBNA)
  • Diagnostic accuracy
  • Ultrasound elastography
  • Fluoroscopy
  • Virtual bronchoscopic navigation
  • Cone-beam CT (CBCT)
  • Rapid on cite evaluation (ROSE)

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 241 KiB  
Article
Diagnostic Yield and Safety of CP-EBUS-TBNA and RP-EBUS-TBLB under Moderate Sedation: A Single-Center Retrospective Audit
by Valencia Lim, Reon Yew Zhou Chin, Adrian Kee, Jeffrey Ng and Kay Choong See
Diagnostics 2022, 12(11), 2576; https://doi.org/10.3390/diagnostics12112576 - 24 Oct 2022
Viewed by 1374
Abstract
Convex probe endobronchial ultrasound transbronchial needle aspirations (CP-EBUS-TBNAs) and radial probe endobronchial ultrasound transbronchial lung biopsies (RP-EBUS-TBLBs) can be performed under moderate sedation or general anesthesia. Moderate sedation is more convenient, however patient discomfort may result in inadequate tissue sampling. General anesthesia ensures [...] Read more.
Convex probe endobronchial ultrasound transbronchial needle aspirations (CP-EBUS-TBNAs) and radial probe endobronchial ultrasound transbronchial lung biopsies (RP-EBUS-TBLBs) can be performed under moderate sedation or general anesthesia. Moderate sedation is more convenient, however patient discomfort may result in inadequate tissue sampling. General anesthesia ensures better patient cooperation but requires more logistics and also carries sedation risks. We aim to describe the diagnostic yield and safety of CP-EBUS-TBNAs and RP-EBUS-TBLBs when performed under moderate sedation at our center. All patients who underwent CP-EBUS-TBNA and/or RP-EBUS-TBLB under moderate sedation, between January 2015 and May 2017, were reviewed. Primary outcomes were defined in regard to the diagnostic yield and safety profile. A total of 336 CP-EBUS-TBNAs and 190 RP-EBUS-TBLBs were performed between January 2015 and May 2017. The mean sedation doses used were 50 mcg of intravenous fentanyl and 2.5 mg of intravenous midazolam. The diagnostic yield of the CP-EBUS-TBNAs and RP-EBUS-TBLBs were 62.5% and 71.6%, respectively. Complication rates were low with: transient bleeding 11.9%, transient hypoxia 0.5%, and pneumothorax 0.1%. None required escalation of care, post procedure. Performing CP-EBUS-TBNAs and RP-EBUS-TBLBs under moderate sedation is safe and provides good diagnostic yield. These procedures should, therefore, be considered as first-line sampling techniques. Full article
(This article belongs to the Special Issue Ultrasound-Guided Diagnosis of Lung Cancer)
10 pages, 633 KiB  
Article
Prognostic Impact of EBUS TBNA for Lung Adenocarcinoma Patients with Postoperative Recurrences
by Ying-Yi Chen, Ying-Shian Chen and Tsai-Wang Huang
Diagnostics 2022, 12(10), 2547; https://doi.org/10.3390/diagnostics12102547 - 20 Oct 2022
Cited by 1 | Viewed by 1075
Abstract
Background: The aim of this study was to verify the importance and the timing of endobronchial ultrasound with transbronchial biopsy (EBUS TBNA) among lung adenocarcinoma patients after radical resection. Methods: We retrospectively reviewed consecutive patients with non-small cell lung cancer (NSCLC) who had [...] Read more.
Background: The aim of this study was to verify the importance and the timing of endobronchial ultrasound with transbronchial biopsy (EBUS TBNA) among lung adenocarcinoma patients after radical resection. Methods: We retrospectively reviewed consecutive patients with non-small cell lung cancer (NSCLC) who had ever received radical resection from January 2002 to December 2021. The patients were divided into two groups, with and without EBUS TBNA, for diagnosis or staging. Results: Of 2018 patients with NSCLC, after surgical resection of lung tumors, there were 232 with recurrences. Under multivariate Cox regression analysis, patients with recurrences who received EBUS TBNA had a statistically higher mean maximum standardized uptake value (SUVmax) (hazard ratio (HR) = 1.115, confidence interval (CI) = 1.004–1.238, p = 0.042) and better survival (HR = 5.966, CI = 1.473–24.167, p = 0.012). Although KM survival analysis showed no statistically significant difference between groups with and without EBUS TBNA (p = 0.072) of lung adenocarcinoma patients with recurrences, patients with mutated epidermal growth factor receptor (EGFR) showed significantly better survival than wild-type EGFR (p = 0.007). Conclusions: The clinical practice of EBUS TBNA is not only for diagnosis, but also for nodal staging. We found that lung adenocarcinoma patients with recurrences who received EBUS TBNA had better overall survival. Therefore, EBUS TBNA is a reliable and feasible tool that could be used in lung adenocarcinoma patients with recurrences for early diagnosis and for adequate tissue specimens for further molecular analysis. Full article
(This article belongs to the Special Issue Ultrasound-Guided Diagnosis of Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop